Federal contract award
75FCMC22F0112
LEAD STATISTICAL AND ANALYTIC SUPPORT CONTRACTOR
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | OFC OF ACQUISITION AND GRANTS MGMT |
| NAICS | 541611 — Administrative Management and General Management Consulting Services |
| PSC | R408 — Program Management/Support Services |
| Parent award / vehicle | 47QRAA18D001P |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $19.9M |
| Current contract value | $19.9M |
| Potential contract value / ceiling | $42.9M |
| Start date | Sep 1, 2022 |
| Current end date | Feb 28, 2028 |
| Potential end date | Feb 28, 2033 |
| Latest award activity | Aug 31, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 11 of 11 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 31, 2026 | P00010 | $4.0M | LSASC |
| Mar 19, 2026 | P00009 | $-43.4K | THE FUNDING FROM OPTION PERIOD 2 TASK 8: TRANSITION IN/OUT FROM CLIN 0022 IN THE AMOUNT OF $46,449.71 AND REDISTRIBUTE THIS FUNDING TO TASK 4: MANAGEMENT (CLIN 0019); AND CORRECT THE SCHEDULE OF DELIVERABLES FOR OPTION PERIOD 3. |
| Feb 27, 2026 | P00008 | $0 | THIS MODIFICATION IS ISSUED TO EXTEND THE PERIOD OF PERFORMANCE (POP) FOR OPTION PERIOD 2 CLINS 0019 AND 0022 FROM FEBRUARY 28, 2026 TO APRIL 15, 2026. |
| Aug 29, 2025 | P00007 | $4.1M | EOI::IMPLEMENTING EO 14222 HHS COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI MODIFICATION TO DESCOPE |
| Apr 29, 2025 | P00006 | $896.4K | THE LEAD STATISTICAL AND ANALYTIC SUPPORT CONTRACTOR (LSASC) FOR THE MEDICARE PART C IMPROPER PAYMENT MEASURE (IPM) WILL PAY MEDICARE ADVANTAGE (MA) PLANS ACCURATELY BY ADJUSTING PAYMENT BASED ON THE EXPECTED EXPENDITURES OF THEIR MEDICARE-ENROLLED P |
| Aug 15, 2024 | P00005 | $3.9M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OY 2, CLIN 0003 |
| Sep 29, 2023 | P00004 | $0 | LEAD STATISTICAL AND ANALYTIC SUPPORT CONTRACTOR (LSASC) FOR THE MEDICARE PART C IMPROPER PAYMENT MEASURE (IPM). |
| Sep 1, 2023 | P00003 | $3.9M | LEAD STATISTICAL AND ANALYTIC SUPPORT CONTRACTOR (LSASC) FOR THE MEDICARE PART C IMPROPER PAYMENT MEASURE (IPM). |
| Mar 22, 2023 | P00002 | $0 | AWARD THE BASE YEAR LEAD STATISTICAL AND ANALYTIC SUPPORT CONTRACTOR (LSASC) FOR THE MEDICARE PART C IMPROPER PAYMENT MEASURE (IPM). |
| Jan 18, 2023 | P00001 | $0 | AWARD THE BASE YEAR LEAD STATISTICAL AND ANALYTIC SUPPORT CONTRACTOR (LSASC) FOR THE MEDICARE PART C IMPROPER PAYMENT MEASURE (IPM). |
| Sep 1, 2022 | 0 | $3.2M | LEAD STATISTICAL AND ANALYTIC SUPPORT CONTRACTOR |
Estimated positioning window
Feb 28, 2032 – Aug 28, 2032
45/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 45/100. Available recorded signals: 40 points.
- Contract end 2033-02-28 (2311 days from calculation)
- +5 points
- 17 historical awards in this buyer and category group
- +15 points
- 11 recorded award transactions
- +10 points
- Latest award action: 2026-08-31
- +5 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.